BACKGROUND: Current neuroendovascular devices, primarily fabricated from nitinol, platinum, and cobalt-chromium alloys, exhibit clinical efficacy but also possess inherent material limitations affecting performance, conformability in complex anatomies, long-term biocompatibility, and cost. This study evaluates the potential of alternative mineral resources, specifically niobium, tantalum, and cobalt, as foundational elements for next-generation neurovascular biomaterials, addressing current device limitations and challenges impeding clinical translation. METHODS: A narrative review was conducted by searching relevant scientific databases (PubMed, Scopus, Web of Science, IEEE Xplore), materials science literature, industry reports, and policy documents. The synthesis focused on neurovascular device materials, global mineral supply chains, and biomedical regulatory pathways, linking material properties to neurointerventional needs. FINDINGS: Niobium, tantalum, and cobalt offer targeted solutions for neurovascular innovation. Tantalum's superior radiopacity addresses poor visibility of current stents. Niobium alloys offer potential for tailored superelasticity, promising more compliant devices. Advanced cobalt-chromium alloys enable stronger, thinner-strutted devices, facilitating miniaturization. Although these minerals are available globally, establishing reliable, medical-grade processing infrastructure and ensuring ethical sourcing remains critical for widespread biomedical application. CONCLUSION: The use of niobium, tantalum, and refined cobalt represents a technically grounded pathway for advancing neurovascular care. Realizing this potential requires leveraging technologically advanced global value chains and international collaboration to drive innovation that is technologically superior and ethically sound.
Tshimbombu et al. (2026) studied this question.